MIR200C (MicroRNA 200c)

News alerts, weekly reports and conference planners

Entrez ID:

miR-200-c overexpression	Lung Non-Squamous Non-Small Cell Cancer	miR-200-c overexpression	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
miR-200-c overexpression	Non Small Cell Lung Cancer	miR-200-c overexpression	Non Small Cell Lung Cancer	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
miR-200-c expression	Pancreatic Cancer	miR-200-c expression	Pancreatic Cancer	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D	erlotinib + mirdametinib Sensitive: D – Preclinical erlotinib + mirdametinib Sensitive : D
miR-200c-3p overexpression	Non Small Cell Lung Cancer	miR-200c-3p overexpression	Non Small Cell Lung Cancer	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D	cisplatin Sensitive: D – Preclinical cisplatin Sensitive : D

Associations(4)